Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

Horn, M; Wolf, P; Wulf, HC; Warloe, T; Fritsch, C; Rhodes, LE; Kaufmann, R; De Rie, M; Legat, FJ; Stender, IM; Solér, AM; Wennberg, AM; Wong, GA; Larkö, O.
Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment.
Br J Dermatol. 2003; 149(6):1242-1249 Doi: 10.1111/j.1365-2133.2003.05600.x
Web of Science PubMed FullText FullText_MUG Google Scholar

Leading authors Med Uni Graz: Horn Michael; Wolf Peter
Co-authors Med Uni Graz: Legat Franz
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Conventional treatment of basal cell carcinoma (BCC) causes morbidity and/or disfigurement in some patients because of the location (e.g. mid-face) and size of the lesion. Following reports that such difficult-to-treat BCC lesions have been treated successfully with topical methyl aminolaevulinate (MAL) photodynamic therapy (PDT), a multicentre study was performed to determine the response of such BCC to MAL-PDT. An open, uncontrolled, prospective, multicentre study was conducted comprising patients with superficial and/or nodular BCC who were at risk of complications, poor cosmetic outcome, disfigurement and/or recurrence using conventional therapy. Patients were given one or two cycles within 3 months of topical MAL-PDT, each consisting of two treatments 1 week apart. Tumour response was assessed clinically at 3 months after the last PDT, with histological confirmation of all lesions in clinical remission. The cosmetic outcome was rated. Patients with a BCC in remission will be followed up for 5 years for recurrence, of which the 24-month follow-up is reported here. Ninety-four patients with 123 lesions were enrolled and treated with MAL-PDT at nine European primary care and referral university hospitals. An independent blinded study review board (SRB) retrospectively excluded nine patients and a total of 15 lesions from the efficacy analysis, for not having a difficult-to-treat BCC according to the protocol. The lesion remission rate at 3 months was 92% (45 of 49) for superficial BCC, 87% (45 of 52) for nodular BCC, and 57% (four of seven) for mixed BCC, as assessed by clinical examination, and 85% (40 of 47), 75% (38 of 51), and 43% (three of seven), respectively, as assessed by histological examination and verified by the SRB. At 24 months after treatment, the overall lesion recurrence rate was 18% (12 of 66). The cosmetic outcome was graded as excellent or good by the investigators in 76% of the cases after 3 months follow-up, rising to 85% at 12 months follow-up, and 94% at 24 months follow-up. Topical MAL-PDT is effective in treating BCC at risk of complications and poor cosmetic outcome using conventional therapy. MAL-PDT preserves the skin and shows favourable cosmetic results.
Find related publications in this database (using NLM MeSH Indexing): Administration, Topical -; Adult -; Aged -; Aged, 80 and over -; Aminolevulinic Acid - administration & dosage; Aminolevulinic Acid - analogs & derivatives; Carcinoma, Basal Cell - drug therapy; Female -; Follow-Up Studies -; Humans -; Male -; Middle Aged -; Photochemotherapy -; Photosensitizing Agents - administration & dosage; Prospective Studies -; Recurrence -; Skin Neoplasms - drug therapy; Treatment Outcome -
Find related publications in this database (Keywords): basal cell carcinoma; cosmetic results; methyl aminolaevulinate; photodynamic therapy